Literature DB >> 15557641

Human antibody responses to a Chlamydia-secreted protease factor.

Jyotika Sharma1, Anthony M Bosnic, Jeanna M Piper, Guangming Zhong.   

Abstract

We have previously identified a chlamydia-secreted protein (designated chlamydial proteasome/protease-like activity factor, or CPAF) in the cytosol of chlamydia-infected cells. Although CPAF is known to degrade host transcription factors required for major histocompatibility complex antigen expression in cultured cells, it is not clear whether CPAF is produced and maintains similar functions in humans infected with chlamydial organisms. We now report that CPAF does not preexist in chlamydial organisms and that CPAF synthesis requires live organism replication in cultured cells. Mice inoculated with live, but not mice inoculated with dead, chlamydial organisms produced a strong antibody response to CPAF, correlating CPAF-specific antibody production with CPAF synthesis in animals. Sera from women diagnosed with Chlamydia trachomatis cervicitis displayed higher levels of antibodies to CPAF than to either chlamydial major outer membrane protein or heat shock protein 60, suggesting that CPAF is both produced and immunogenic during human chlamydial infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557641      PMCID: PMC529132          DOI: 10.1128/IAI.72.12.7164-7171.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 2.  New insights into a persistent problem -- chlamydial infections.

Authors:  Richard P Morrison
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 3.  The cellular paradigm of chlamydial pathogenesis.

Authors:  Richard S Stephens
Journal:  Trends Microbiol       Date:  2003-01       Impact factor: 17.079

4.  Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera.

Authors:  M Sanchez-Campillo; L Bini; M Comanducci; R Raggiaschi; B Marzocchi; V Pallini; G Ratti
Journal:  Electrophoresis       Date:  1999-08       Impact factor: 3.535

5.  Persistent Chlamydia trachomatis infections resist apoptotic stimuli.

Authors:  D Dean; V C Powers
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes.

Authors:  J U Igietseme; A Murdin
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Expression and translocation of chlamydial protease during acute and persistent infection of the epithelial HEp-2 cells with Chlamydophila (Chlamydia) pneumoniae.

Authors:  Dagmar Heuer; Volker Brinkmann; Thomas F Meyer; Agnes J Szczepek
Journal:  Cell Microbiol       Date:  2003-05       Impact factor: 3.715

8.  Inhibition of host cell cytokinesis by Chlamydia trachomatis infection.

Authors:  Whitney Greene; Guangming Zhong
Journal:  J Infect       Date:  2003-07       Impact factor: 6.072

9.  Restricted fusion of Chlamydia trachomatis vesicles with endocytic compartments during the initial stages of infection.

Authors:  Marci A Scidmore; Elizabeth R Fischer; Ted Hackstadt
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

10.  Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors.

Authors:  G Zhong; P Fan; H Ji; F Dong; Y Huang
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  46 in total

1.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

2.  A Chlamydia trachomatis OmcB C-terminal fragment is released into the host cell cytoplasm and is immunogenic in humans.

Authors:  Manli Qi; Siqi Gong; Lei Lei; Quanzhong Liu; Guangming Zhong
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

3.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

4.  The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.

Authors:  Cathi Murphey; Ashlesh K Murthy; Patricia A Meier; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  Cell Immunol       Date:  2006-11-20       Impact factor: 4.868

5.  A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.

Authors:  Jie Wang; Lili Chen; Fan Chen; Xiaoyun Zhang; Yingqian Zhang; Joel Baseman; Sondra Perdue; I-Tien Yeh; Rochelle Shain; Martin Holland; Robin Bailey; David Mabey; Ping Yu; Guangming Zhong
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

6.  Chlamydia trachomatis secretion of hypothetical protein CT622 into host cell cytoplasm via a secretion pathway that can be inhibited by the type III secretion system inhibitor compound 1.

Authors:  Siqi Gong; Lei Lei; Xiaotong Chang; Robert Belland; Guangming Zhong
Journal:  Microbiology (Reading)       Date:  2011-01-13       Impact factor: 2.777

7.  Preparation and evaluation of monoclonal antibodies against chlamydial protease-like activity factor to detect Chlamydia pneumoniae antigen in early pediatric pneumonia.

Authors:  J Zheng; T Ding; Z Chen; H Fang; H Li; H Lu; Y Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-03-12       Impact factor: 3.267

8.  A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Authors:  Weidang Li; Ashlesh K Murthy; Gopala Krishna Lanka; Senthilnath L Chetty; Jieh-Juen Yu; James P Chambers; Guangming Zhong; Thomas G Forsthuber; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2013-10-01       Impact factor: 3.641

9.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

10.  High throughput sequencing and proteomics to identify immunogenic proteins of a new pathogen: the dirty genome approach.

Authors:  Gilbert Greub; Carole Kebbi-Beghdadi; Claire Bertelli; François Collyn; Beat M Riederer; Camille Yersin; Antony Croxatto; Didier Raoult
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.